Eam Investors, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

  • $556 Million
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.19 - $7.95 $624,431 - $1.18 Million
149,029 New
149,029 $894,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email